BRIUMVI

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, United States

Active ingredients

The drug BRIUMVI contains one active pharmaceutical ingredient (API):

1 Ublituximab UNII U59UGK3IPC - UBLITUXIMAB

Ublituximab is a chimeric monoclonal antibody that selectively targets CD20-expressing cells. CD20 is a cell surface antigen found on pre-B cells, mature and memory B cells but not expressed on lymphoid stem cells and plasma cells. The binding of ublituximab to CD20 induces lysis of CD20+ B cells. Read about Ublituximab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BRIUMVI Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AG14		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG14

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3036710
Country: FR	Base de données publique des médicaments	Identifier(s): 61216870
Country: IT	Agenzia del Farmaco	Identifier(s): 050698012
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097211
Country: US	FDA, National Drug Code	Identifier(s): 73150-150